# Targeting the Gut to Improve Seizure Control in CDKL5 Deficiency Disorder (CDD)

> **NCT06448663** · NA · RECRUITING · sponsor: **University of Milan** · enrollment: 20 (estimated)

## Conditions studied

- CDKL5

## Interventions

- **DIETARY_SUPPLEMENT:** alpha-lactalbumin, fructooligosaccharides, inulin
- **DIETARY_SUPPLEMENT:** alpha-lactalbumin, sodium butyrate, fructooligosaccharides, inulin

## Key facts

- **NCT ID:** NCT06448663
- **Lead sponsor:** University of Milan
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2025-01-31
- **Final completion:** 2025-04-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-06-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06448663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06448663, "Targeting the Gut to Improve Seizure Control in CDKL5 Deficiency Disorder (CDD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06448663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*